Revised SPCs: Cosentyx (secukinumab) 150 mg solution for injection in pre-filled and syringe
SPCs revised to include headache, nausea and fatigue as common (≥ 1/100 to < 1/10) undesirable effects of treatment.
Source:
electronic Medicines compendium